These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15464424)

  • 41. Unbuckling lipodystrophy from insulin resistance and hypertension.
    Hegele RA; Leff T
    J Clin Invest; 2004 Jul; 114(2):163-5. PubMed ID: 15254581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.
    Duan SZ; Ivashchenko CY; Whitesall SE; D'Alecy LG; Duquaine DC; Brosius FC; Gonzalez FJ; Vinson C; Pierre MA; Milstone DS; Mortensen RM
    J Clin Invest; 2007 Mar; 117(3):812-22. PubMed ID: 17304352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.
    Agostini M; Schoenmakers E; Mitchell C; Szatmari I; Savage D; Smith A; Rajanayagam O; Semple R; Luan J; Bath L; Zalin A; Labib M; Kumar S; Simpson H; Blom D; Marais D; Schwabe J; Barroso I; Trembath R; Wareham N; Nagy L; Gurnell M; O'Rahilly S; Chatterjee K
    Cell Metab; 2006 Oct; 4(4):303-11. PubMed ID: 17011503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome.
    Hegele RA
    Trends Endocrinol Metab; 2003 Oct; 14(8):371-7. PubMed ID: 14516935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.
    Cataldi S; Costa V; Ciccodicola A; Aprile M
    Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes.
    Tan K; Kimber WA; Luan J; Soos MA; Semple RK; Wareham NJ; O'Rahilly S; Barroso I
    Diabetes; 2007 Mar; 56(3):714-9. PubMed ID: 17327441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics.
    Chatterjee VK
    Horm Res; 2003; 60 Suppl 3():51-5. PubMed ID: 14671397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prepubertal onset of type 2 diabetes in Shashi-Pena syndrome due to ASXL2 mutation.
    Murphy SA; O'Rourke NE; O'Grady MJ
    Am J Med Genet A; 2022 Sep; 188(9):2803-2807. PubMed ID: 35716351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure.
    Tsai YS; Xu L; Smithies O; Maeda N
    Proc Natl Acad Sci U S A; 2009 Nov; 106(45):19084-9. PubMed ID: 19884495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility.
    Gilardi F; Winkler C; Quignodon L; Diserens JG; Toffoli B; Schiffrin M; Sardella C; Preitner F; Desvergne B
    Metabolism; 2019 Jun; 95():8-20. PubMed ID: 30878493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pathogenic genes and adipogenic differentiation transcription factor PPARγ associated with congenital lipodystrophic diabetes].
    Zhang X; Qin Y; Lin F
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Aug; 36(8):844-847. PubMed ID: 31400143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Human Genome Project on medical practice.
    Lele RD
    J Assoc Physicians India; 2001 Oct; 49():959-61. PubMed ID: 11848325
    [No Abstract]   [Full Text] [Related]  

  • 53. [The role of PPARgamma in the onset of type 2 diabetes].
    Hara K; Yamauchi T; Kubota N; Tobe K; Yamazaki T; Nagai R; Kadowaki T
    Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):317-24. PubMed ID: 14501167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PPAR gamma and human metabolic disease.
    Semple RK; Chatterjee VK; O'Rahilly S
    J Clin Invest; 2006 Mar; 116(3):581-9. PubMed ID: 16511590
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipodystrophy, Diabetes and Normal Serum Insulin in PPARγ-Deficient Neonatal Mice.
    O'Donnell PE; Ye XZ; DeChellis MA; Davis VM; Duan SZ; Mortensen RM; Milstone DS
    PLoS One; 2016; 11(8):e0160636. PubMed ID: 27505464
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
    Broekema MF; Savage DB; Monajemi H; Kalkhoven E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):715-732. PubMed ID: 30742913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms with Polycystic Ovary Syndrome.
    Joob B; Wiwanitkit V
    Ann Nutr Metab; 2019; 75(3):197. PubMed ID: 31618730
    [No Abstract]   [Full Text] [Related]  

  • 58. Computational analysis of single nucleotide polymorphisms (SNPs) in PPAR gamma associated with obesity, diabetes and cancer.
    Stalin A; Lin D; Josephine Princy J; Feng Y; Xiang H; Ignacimuthu S; Chen Y
    J Biomol Struct Dyn; 2022 Mar; 40(4):1843-1857. PubMed ID: 33089758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Epigenomic contribution in the onset of diabetes].
    Sakai J; Inagaki T
    Nihon Rinsho; 2012 May; 70 Suppl 3():196-201. PubMed ID: 22768519
    [No Abstract]   [Full Text] [Related]  

  • 60. [Mutations and polymorphisms: clinical significance in cardiology].
    Rubattu S; Zirpoli L; Volpe M
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):1019-22. PubMed ID: 12497870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.